Rodman & Renshaw reiterated its Agenus AGEN Market Perform rating and $2 price target in a research report published today.
In the report, Rodman & Renshaw states, " We are reiterating our Market Outperform / Speculative Risk rating on Agenus with a 12-month target price of $2, based on a comparable company analysis to value the oncology programs in combination with a net present value analysis for the potential contribution of future QS-21 royalty revenue to the company's valuation."
Shares of Agenus were trading at $0.81 at the time of posting, down 0.61% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in